Ridley-Tree Cancer Center Opens Radiation Oncology Clinical Trial for Breast Cancer Patients

By Giving List Staff   |   July 20, 2022
Shane Cotter, MD, PhD, Ridley-Tree Cancer Center Radiation Oncologist; Heidi Heitkamp, PhD, Ridley-Tree Cancer Center Clinical Research Department Manager; Clarence Thompson, Director, Radiation Oncology, Ridley-Tree Cancer Center

Ridley-Tree Cancer Center announced the opening of a radiation oncology clinical trial for breast cancer patients, and the enrollment of the trial’s first patient here in Santa Barbara. This marks the organization’s commitment to keep the central coast at the forefront of modern cancer care. The trial focuses on whether patients with early stage breast cancer between the ages of 50 and 69 who meet certain criteria can avoid radiation treatment and still receive good outcomes.  

“Historically, radiation therapy for breast cancer was a one-size-fits-all approach, including six weeks of radiation regardless of the aggressiveness of the disease,” explains Shane Cotter, MD, PhD, Radiation Oncologist and principal investigator for this trial. “Our understanding of the disease has evolved over time, such that oncologists have begun to de-escalate treatment for less aggressive subsets. While one does not want to under-treat, we do not want to over-treat those patients we expect to still do very well with less aggressive therapies.” Cotter adds that for younger women, the tendency has been to treat routinely with radiation. Studies in carefully-selected women 70 and over have shown no survival benefit to adding radiation, he notes. “In older women, sometimes after surgery, just the anti-hormone pill is enough protection for the breast and body, because the risks are low. The research shows with this treatment plan, women in that age group can forgo the radiation and still do very well. So we are now asking, if it’s true for the older women, is it is also true for younger women ages 50 to 69, who are very carefully selected.”

This nationwide trial that Ridley-Tree is joining seeks to enroll 1,714 women from 339 different study sites across the country. These patients will continue the treatment course decided on with their medical team, but half will no longer receive radiation therapy. For those who do receive radiation, it will follow standard of care. “Participants in this trial will go through a process called randomization with a 50/50 chance of study arm assignment. Who ends up with radiation treatment is not decided by us, the study will assign women to one arm of the trial or the other,” shares Heidi Heitkamp, PhD, Clinical Research Department Manager. Trial participant’s care will be followed for ten years, with the primary study completion date in 2026, and final results expected in 2041.

Generally, qualifying trial candidates have small stage 1, estrogen receptor-positive tumors with low risk of recurrence that were surgically removed. The specific hormone blocking treatment used by trial participants is determined by a patient’s medical oncologist, not the study organizers. Ridley-Tree’s Clinical Research Department and Dr. Cotter will fully evaluate the medical history of any woman volunteering to join the trial, to determine eligibility. 

“It’s exciting to have a trial that is on the leading edge of how we make important decisions about radiation treatment, and to be working alongside many trial sites and large academic centers,” remarks Dr. Cotter. “We always look forward to opening studies that we think ask the best questions, and best serve the patients in our community.” Ridley-Tree is participating in this trial via its new affiliation with the NRG Oncology Network, an NCI-funded collaborative. NRG broadens Ridley-Tree’s study portfolio beyond surgical and medical oncology. Ridley-Tree’s Clinical Research Department also partners with the US Oncology Research Network, leading pharmaceutical companies and universities. Through these networks, our center’s oncologists and researchers collaborate to identify and initiate trials based on the science and the need in our community. The Clinical Research program at Ridley-Tree Cancer Center is made possible thanks to generous support from the Cancer Foundation of Santa Barbara.

For more information on this specific clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT04852887

For more information on Ridley-Tree’s Clinical Research Department visit research.ridleytreecc.org


Ridley-Tree Cancer Center has been at the forefront of comprehensive outpatient cancer care on the central coast for more than 70 years. We have the expertise and technology of an academic center complemented by a personalized approach to care. Ridley-Tree Cancer Center’s team of highly-trained and compassionate physicians and staff care for patients with the most advanced surgical, medical and radiation oncology treatments. Through the use of cutting-edge technology, global clinical trials, and research-based supportive care and wellness programs, we provide our patients with every opportunity for successful treatment and recovery.


The Cancer Foundation of Santa Barbara

Donate now!

(805) 898-2187
Executive Director: Lori Willis

Begin to Build a Relationship

We know you care about where your money goes and how it is used. Connect with this organization’s leadership in order to begin to build this important relationship. Your email will be sent directly to this organization’s director of development and/or Executive Director.

Cancer care is often expensive and leaves many residents unable to afford potentially lifesaving treatments. Support of the AJM Fund means that world-class care offered by Ridley-Tree Cancer Center’s medical team will continue to be available to everyone in our community who faces a cancer diagnosis, allowing them to focus on their recovery without the burden of the inevitable accompanying financial challenges.
Art Merovick

In Art’s Honor

In 2011, in order to advance its mission of providing advanced cancer care to anyone in the community regardless of financial ability, the Cancer Foundation established the AJM Endowment Fund for Patient Assistance, created in honor of Art Merovick for his many years of service to the Foundation. The AJM Fund provides financial assistance for medical treatment, procedures, and co-pay obligations for qualified patients. In keeping with the 72-year mission of the Foundation, it is a charitably supported endowment that ensures access to the excellent care of the Ridley-Tree Cancer Center for all patients, regardless of their financial means.

Board of Trustees

Denny Bacon
Kristen Blabey – Secretary
Andy Chou
C. Michael Cooney – Chair
Shane Cotter, MD, PhD
Larry Dam
Frank Foster
Vicki Hazard
Priscilla Higgins, PhD – Vice Chair
Patty MacFarlane – Treasurer
William Meeker
Val Montgomery
Richard Nagler
Carola Nicholson
Charles Petersen  
Amalia Priego
Kimberly Schizas
George Tharakan
Thomas H. Weisenburger, MD
Katina Zaninovich